|
|
Volumn 6, Issue 2, 2006, Pages 129-131
|
|
Personalized medicine: Challenges in assessing and capturing value in the commercial environment '...The development of drugs that are highly targeted to patients most likely to benefit holds enormous promise for global healthcare'
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CETUXIMAB;
DIAGNOSTIC AGENT;
GEFITINIB;
HERCEPTEST;
IMATINIB;
TRASTUZUMAB;
DRUG;
BREAST CANCER;
CLINICAL TRIAL;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESEARCH;
EDITORIAL;
EVIDENCE BASED MEDICINE;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE;
HEALTH ECONOMICS;
HUMAN;
MEDICAL LITERATURE;
MEDICAL RESEARCH;
ONCOLOGY;
PHYSICIAN;
RISK FACTOR;
BIOLOGY;
DIAGNOSTIC PROCEDURE;
DRUG THERAPY;
ECONOMICS;
GENOMICS;
HEALTH SERVICE;
MEDICAL GENETICS;
METHODOLOGY;
PHARMACEUTICS;
PHARMACOGENETICS;
COMPUTATIONAL BIOLOGY;
DRUG INDUSTRY;
DRUG THERAPY;
GENETICS, MEDICAL;
GENOMICS;
HUMANS;
MOLECULAR DIAGNOSTIC TECHNIQUES;
PERSONAL HEALTH SERVICES;
PHARMACEUTICAL PREPARATIONS;
PHARMACOGENETICS;
TECHNOLOGY, PHARMACEUTICAL;
|
|
EID: 33744752433
PISSN: 14737159
EISSN: 17448352
Source Type: Journal
DOI: 10.1586/14737159.6.2.129 Document Type: Editorial |
|
Times cited : (9)
|
|
References (0)
|
